



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Monday,
                        11 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)






                                    LOK SABHA
                                





STARRED   


                                    QUESTION NO:
                                

67






                                    ANSWERED ON: 
                                

05.02.2021






Research in Ayurvedic Medicines




Sanjeev Kumar Singari














                        Will the Minister of





AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)


                        be pleased to state:-















                                                    Will the Minister of AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state: (a) whether Government has framed any guidelines for research/clinical trials of Ayurvedic medicines following the rules/protocols set by Organization for Economic Co-operation and Development (OECD), Committee for Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and Institutional Ethics Committee; (b) whether mandatory registration in Clinical Trials Registry of India is being followed; (c) if the replies to parts (a) and (b) above be in negative, the steps followed to regulate clinical trials of Ayurvedic drugs in the country; (d) whether Government has mandated evidence based trials of Ayurvedic drugs prior to their introduction into the market; (e) if so, the details thereof including the various trials that were conducted during the last six years; and (f) if not, the reasons therefor including the steps taken to ensure the safety and efficacy of Ayurvedic drugs?






ANSWER




                                                        ANSWERTHE MINISTER OF STATE(IC) OF THE MINISTRY OF YOUTH AFFAIRS AND SPORTS AND ADDITIONAL CHARGE OF MINISTER OF STATE (IC) OF THE MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (SHRI KIREN RIJIJU)  (a)	& (f):  A statement is laid on the Table of the House STATEMENT REFERRED TO IN REPLY TO LOK SABHASTARRED QUESTION NO. 67 * FOR 5TH  FEBRUARY, 2021a)	Yes, Sir. The Ministry of AYUSH has framed Good Clinical Practice guidelines (GCP) for clinical trials in Ayurveda, Siddha and Unani (ASU) medicine in March 2013 with a wide consultative process on the basis of Central Drugs Standard Control Organization’s (CDSCO) publication on ‘GCP Guidelines for Clinical Trials on Pharmaceutical Products (2001) and imbibes the inputs received form Indian Council of Medical Research (ICMR), CDSCO, Central Councils for Research in ASU systems, experts from Research Institutions, Teaching Institutions, State Regulatory Bodies and representatives from ASU drugs manufacturing industries. As per the rule 1.18 of GCP Guidelines, it is mandatory to have Ethics Committee comprising of medical / scientific and nonmedical / non-scientific members.b)	Yes, Sir.c)	Does not arise.	d)	As per rule 158 (B) of the Drugs & Cosmetics Act, 1940, the Ayurvedic formulations/ medicines specified in section 3(a) of Drugs & Cosmetics Act, 1940 require proof of effectiveness to be used for new indication; and for Ayurvedic formulations/ medicines specified in section 3(h) of the Act.e)	The clinical trials conducted during the last six years are in the areas of Bronchial Asthma (Tamaka Swasa), Essential Hypertension, Anxiety Neurosis, Cervical Spondylosis, Urolithiasis, Uterine Fibroid, Obesity, Computer Vision Syndrome, Menopausal syndrome, Sciatica, Allergic Conjunctivitis, Influenza like Illness, Fissure in Ano, Anorectal Fistula, Allergic Rhinitis, Primary Dysmenorrheoa, leucorrhoea, Malabsorption Syndrome, Dysfunctional Uterine Bleeding, Age Related Macular Degeneration Symptoms, Hyperacidity/Non ulcer dyspepsia, Eczema, Mental retardation (Manasamandata) in children, Local Non-Metastatic Breast Cancer, Dengue Fever, Type 2 Diabetes Mellitus, high grade serous epithelial ovarian cancer, Ante-Natal care, chronic Filarial Lymphoedena, Prevention and Control of Cancer, Diabetes, Cardiovascular diseases & Stroke, COVID-19 etc. The clinical safety and efficacy of around 92 classical formulations in 40 disease conditions has been generated on the basis of preclinical and clinical safety studies as per the guidelines. The details are at annexure-I.f)	Does not arise.	
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113200888







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







